The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy

Published:2017-12-18 Issue:7 Volume:110 Page:777-786
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

McKenzie Jodi A¹,Mbofung Rina M¹,Malu Shruti¹,Zhang Min²,Ashkin Emily¹,Devi Seram³,Williams Leila¹,Tieu Trang⁴,Peng Weiyi¹,Pradeep Sunila⁵,Xu Chunyu¹,Zorro Manrique Soraya¹,Liu Chengwen¹,Huang Lu¹,Chen Yuan¹,Forget Marie-Andree¹,Haymaker Cara¹,Bernatchez Chantale¹,Satani Nikunj⁶,Muller Florian⁶,Roszik Jason¹,Kalra Ashish⁷,Heffernan Timothy⁴,Sood Anil⁵⁸,Hu Jianhua⁹,Amaria Rodabe¹,Davis R Eric²,Hwu Patrick¹

Affiliation:

1. Department of Melanoma Medical Oncology

2. Department of Lymphoma/Myeloma

3. Department of Sarcoma Medical Oncology

4. Institute for Applied Cancer Science

5. Department of Gynecologic Oncology and Reproductive Medicine

6. Department of Cancer Imaging Systems

7. The University of Texas MD Anderson Cancer Center, Houston, TX; Merrimack Pharmaceuticals, Cambridge, MA

8. Center for RNA Interference and Non-coding RNA

9. Department of Biostatistics

Funder

National Institutes of Health

Ovarian Cancer Research Fund

Cancer Prevention and Research Institute of Texas

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/110/7/777/25124844/djx257.pdf

Reference33 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010

3. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med.,2012

4. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial;Ribas;Lancet Oncol,2015

5. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N J Engl Med.,2011

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review;Cancers;2024-02-06

2. Activation of STING by the Novel Liposomal TLC388 Enhances the Therapeutic Response to Anti-PD-1 Antibodies in Combination with Radiotherapy;2024-01-30

3. Metformin‐Mediated Immunosuppressive Microenvironment Remodeling in Combination with Chemotherapy via a Spatial‐Specific Multi‐Responsive Carrier‐Free Self‐Assembled Nanoparticle;Advanced Functional Materials;2024-01-28

4. ANTIBODY-DRUG CONJUGATES IN TRIPLE NEGATIVE BREAST CANCER;Clinical Breast Cancer;2024-01

5. An “AND” Logic‐Gated Prodrug Micelle Locally Stimulates Antitumor Immunity;Advanced Materials;2023-12-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3